Home Breathing Exercises for Long COVID Heart Patients

A cheap, accessible rehab idea has one real advantage: people might actually be able to do it

Long COVID rehabilitation has a basic logistics problem. Many patients are too wiped out for standard programs, and people with cardiovascular disease often face extra barriers to cardiac rehab in the first place. A home routine that needs no equipment, no clinic gym, and no heroic scheduling would solve a real problem if it worked.

A 2024 randomized study by Dwiputra et al. offers a reason to pay attention. In 46 adults with long COVID and cardiovascular comorbidities, researchers tested a 12-week home-based program of breathing and chest mobility exercises added to home aerobic exercise and standard cardiac rehabilitation. The control group received the home-based cardiac rehabilitation program alone. The intervention group improved on several objective measures of cardiorespiratory function, including peak expiratory flow rate, peak cough flow, six-minute walk distance, and chest excursion. Quality-of-life scores and the inflammatory markers C-reactive protein and D-dimer did not improve between groups at 12 weeks.

That is the whole story in one sentence: a physiological signal, not a finished protocol. The trial was small, single-blind, and unable to isolate which part of the intervention did the work. It still matters because this patient group has very little controlled evidence aimed at it.

What the trial found, and what it did not

The Dwiputra trial took place at a tertiary cardiovascular center in Jakarta, Indonesia. Investigators randomized 23 patients to the added breathing and chest mobility program and 23 to control. The breathing program ran three times per week for 12 weeks, with physician supervision by video conference. The study reported statistically significant gains in objective functional outcomes in the intervention arm relative to standard care alone. Those are useful outcomes. If someone walks farther in a six-minute walk test and generates better expiratory and cough flow, something changed.

But the result has a large asterisk. The published summary available here does not provide the exact change in meters for the six-minute walk test or the percentage change for peak expiratory flow. That means readers cannot judge whether the gain crossed a clinically meaningful threshold rather than a statistically significant one. In cardiac rehabilitation, the minimal clinically important difference for the six-minute walk test often falls somewhere around 25 to 54 meters, but that benchmark has not been established specifically for long COVID in the evidence reviewed here.

The study also did not show improvement in EQ-5D quality-of-life scores, CRP, or D-dimer. That does not erase the functional findings, but it narrows what can be claimed. The patients walked farther and had better respiratory performance on testing. The study did not show that they felt better overall or that systemic inflammation measurably improved over 12 weeks.

Why the mixed result makes sense

This split between objective function and subjective recovery fits the broader long COVID literature. A 2025 population-based study by Peter et al. found that fatigue, dyspnea, and other symptoms can persist well into the second year after infection. Long COVID does not always move in a straight line where better test performance quickly becomes better daily life. Bodies are rude that way.

It also fits what rehabilitation studies have found more generally. A 2025 meta-analysis by Li et al. concluded that pulmonary rehabilitation in long COVID improves physical capacity, dyspnea, and quality of life overall, but effects on lung function and fatigue were inconsistent across trials. A 2023 JAMA Network Open meta-analysis similarly found that rehabilitation improves physical capacity in adults with post-COVID condition, while also noting that clinical guidelines still rely heavily on expert opinion because the trial base remains thin.

So the Dwiputra result is not weird. It fits an emerging pattern: rehab tends to improve objective function more consistently than it improves fatigue, quality of life, or biomarkers. That is useful, but it is not the same as recovery in the way patients mean it.

Why breathing might help at all

The simplest explanation is mechanical. If chest mobility improves thoracic movement and breathing exercises lower the work of breathing, exercise may become less ventilatorily expensive. That theory is plausible, but this trial did not directly prove it.

There is also an autonomic hypothesis. A 2025 case-control study by Mauro et al. found that slow-paced breathing significantly modulated heart rate variability in healthcare workers with long COVID compared with controls. That does not prove that autonomic changes caused the walking gains in Dwiputra's trial, but it supports a biologically coherent pathway. Breathing exercises may affect more than lungs and chest wall mechanics.

Even so, long COVID exercise intolerance is unlikely to yield to a single neat trick. A 2024 systematic review by Gomes-Neto et al. found that impaired cardiorespiratory fitness after COVID reflects multiple central and peripheral factors. That is a polite way of saying the problem is messy. Any intervention aimed mainly at breathing mechanics will probably help some part of the syndrome, not all of it.

How this trial fits the wider evidence

On the supportive side, several reviews point in the same direction. Besides the Li and Pouliopoulou meta-analyses, a 2025 systematic review by Andrade et al. reported that physical exercise interventions improved functional physical performance in long COVID. A 2024 meta-analysis by Deng et al. found rehabilitation benefits in older adults with long COVID, a group that overlaps with the higher cardiovascular risk population in practice.

The closest cardiovascular analog is not long COVID at all, but ischemic heart disease. A 2024 meta-analysis by Fabero-Garrido et al. found that respiratory muscle training improved exercise capacity, health-related quality of life, and pulmonary function in people with ischemic heart disease, with no serious adverse events reported across supervised protocols. That does not validate a home long COVID program, but it makes the general idea less far-fetched for cardiac patients.

There is also a reason not to overrate the home protocol. A 2024 pilot trial by Doehner et al. found that supervised inpatient intermittent hypoxic-hyperoxic training improved exercise capacity and function in long COVID. Different intervention, different setting, different level of supervision. Still, it suggests that more intensive and closely monitored rehab may produce larger or faster effects than a home routine. The Dwiputra protocol may be a floor, not a ceiling.

The study's biggest limitation is not the small sample, though that is a problem too

Yes, 46 participants is a small trial. It is too small for confident subgroup analysis, and too small to settle questions about who benefits most. A 2024 study by Garbsch et al. found sex-specific differences in rehabilitation response after post-COVID syndrome. In a sample this small, meaningful differences by sex could easily disappear into the average.

But the larger methodological issue is co-intervention. The intervention arm did not receive breathing and chest mobility work alone. It received breathing exercises, chest mobility exercises, home aerobic exercise, and standard cardiac rehabilitation. The control group received standard home-based cardiac rehabilitation. That design tests a package against standard care, not breathing exercises in isolation. If the package worked, the trial cannot tell us how much credit belongs to the breathing component versus simply doing more exercise overall.

Other problems matter too. Participants knew which group they were in, so expectation and performance bias are possible. Adherence monitoring relied partly on video conferencing, but the study does not describe objective verification such as heart-rate monitoring or accelerometry. There is no long-term follow-up beyond 12 weeks. Most important for a medically complex population, the study does not report adverse events such as arrhythmia, syncope, or worsening cardiovascular symptoms during the home program.

What readers should do with this

If you have long COVID without cardiovascular disease, the broader evidence supports structured breathing work and rehabilitation as a reasonable, low-cost way to improve functional capacity. The evidence is strongest for objective performance measures, not for fatigue cure narratives.

If you have long COVID plus cardiovascular comorbidities, this trial does not justify copying a home protocol from the internet and hoping for the best. The participants were treated through a tertiary cardiovascular center with clinical oversight. That is not a trivial detail. The evidence here supports asking for supervised rehab with a breathing component, not self-prescribing a half-validated routine because it looks harmless.

The most honest takeaway is simple: home breathing and chest mobility exercises may help long COVID patients with cardiovascular disease walk farther and breathe better on testing, but one small randomized trial has not shown that they feel better, and it has not established a proven stand-alone protocol.

That is enough to justify more research and enough to interest clinicians who see these patients fall through the cracks. It is not enough to pretend the answer has arrived. Science rarely shows up with a marching band.